Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERPASS
2024-512652-38-00Phase 2Completed
- Sponsor
- Replimune Group, Inc.
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial in cutaneous squamous cell carcinoma (cSCC) comparing Cemiplimab monotherapy with Cemiplimab + RP1 (2 arms). Primary endpoints: Objective response rate (ORR) by blinded independent review and Complete response rate (CRR) by blinded independent review. Started Nov 2024; status: completed.
02
Drugs
cemiplimabvusolimogene oderparepvec
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2024-512652-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512652-38-00.